華多利集團(01139.HK):上市委員會同意延長限期提交上市申請 繼續停牌
格隆匯 8 月 4日丨華多利集團(01139.HK)發佈公告,由於需要更多時間籌備上市申請,故公司已於2020年6月11日向聯交所提出申請,徵求其同意將截止日期由2020年6月19日延後至2020年9月11日。2020年7月17日,公司接獲聯交所函件,知會公司有關上市委員會已同意延長限期,以讓公司於2020年9月11日或之前提交上市申請。倘基於任何原因公司未能如此行事或復牌建議未能進行,則聯交所將取消公司股份於聯交所的上市地位。
應公司要求,公司股份已於聯交所暫停買賣,並將維持暫停買賣直至另行通知為止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.